Categories: News

Bybit x Block Scholes Quarterly Report: Rise of Perp DEXs — and How to Catch the Opportunity

DUBAI, UAE, Oct. 17, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has released its latest Bybit x Block Scholes Crypto Derivatives Analytics Report.

- Advertisement -

Key Highlights:

- Advertisement -
  • Perp DEXs surge in adoption: Decentralized perpetual exchanges (perp DEXs) have seen explosive growth since late 2024, reshaping the trading landscape with speed, accessibility, and on-chain transparency.
  • Hyperliquid dominates: Hyperliquid captured 58% of trading volume across the top eight perp DEXs in 2025, with daily fee generation consistently outpacing Uniswap since May. The exchange has contributed up to 60% of total fees across major blockchains.
  • Why traders are migrating: Traders are shifting from centralized exchanges (CEXs) and spot DEXs to perp DEXs due to frictionless onboarding, self-custody, faster token listings, competitive fee structures, and leverage up to 100x.
  • HYPE token performance: Hyperliquid’s native token, HYPE, has surged more than six-fold since April 2025, supported by a 97% revenue buyback program. However, a major token unlock beginning November 29, 2025, could dilute this momentum unless buybacks scale further.

Perp DEXs are increasingly viewed as the next frontier in crypto trading, offering a blend of speed, security, and transparency that rivals traditional centralized platforms. With traders prioritizing autonomy and efficient market access, the shift toward decentralized perpetual trading has accelerated throughout 2025.

- Advertisement -

The report underscores how Hyperliquid’s innovative tokenomics, user-friendly design, and liquidity incentives have positioned it as a frontrunner in this sector. However, with challenges such as liquidity fragmentation and upcoming token unlocks, the market remains dynamic, presenting both opportunities and risks for traders and investors alike.

- Advertisement -

The full analysis is available in the Bybit x Block Scholes Crypto Derivatives Analytics Report.

- Advertisement -

#Bybit / #CryptoArk /#BybitResearch / #BybitLearn

- Advertisement -

About Bybit

- Advertisement -

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

- Advertisement -

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

- Advertisement -


Discord
 | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

- Advertisement -

Logo – https://mma.prnewswire.com/media/2267288/Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/bybit-x-block-scholes-quarterly-report-rise-of-perp-dexs–and-how-to-catch-the-opportunity-302587558.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

3 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

7 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

7 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

7 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

7 hours ago